According to preliminary test results, all four Chinese vaccines can trigger a rapid immune response, and the vaccine developed by China’s Koxing is better suited to vaccination in third-world countries than the new crown vaccines currently developed by U.S. drugmakers Pfizer and Moderna. China’s coronavirus vaccine and four other experimental vaccines are reportedly currently undergoing late-stage trials to determine their effectiveness in preventing new coronavirus pneumonia.
According to preliminary test results, the vaccine developed by China’s Koxing Company triggered a rapid immune response. “Our results suggest that the Koxing vaccine can induce a rapid antibody response after four weeks of immunization by injecting two doses of the vaccine 14 days apart,” said Zhu Fengcai, one of the authors of the study, published in a peer-reviewed paper published in the medical journal The Lancet Infectious Diseases. “We believe this makes the vaccine suitable for emergency use during a new crown pandemic,” Zhu said in a statement released with the paper. The vaccine is currently being tested in three phases in Indonesia, Brazil and Turkey, the final results of which will be released after the end of phase III.
Compared to vaccines from U.S. drugmakers Pfizer and Moderna, the vaccine can be stored in refrigerators at temperatures of 2 to 8 degrees Celsius and can remain stable for up to three years, according to reports. Pfizer’s vaccine must be stored and shipped at minus 70 degrees Celsius, while Moderna’s vaccine is expected to last 30 days at normal refrigerator temperatures, but needs to be kept at minus 20 degrees Celsius for more than six months. Compared to the two mRNA vaccines in the United States, which require ultra-low-temperature storage, China’s Koxing’s new crown inactivated vaccine is suitable for most third-world countries around the world that cannot provide ultra-low-temperature storage.
According to peer-reviewed papers, two other vaccines in China’s new crown vaccine contingency plan (both developed by the relevant research institutes of the National Pharmaceutical Group) and another vaccine from China’s Koxing Company have also been shown to be safe in early and medium-term trials and can trigger an immune response. Brazil and Indonesia are currently considering a new coronavirus vaccine against China in the coming months. Ricardo Palacios, manager of brazil’s Butantan Sanctuary Institute, which is conducting the third phase of the Kosing vaccination trial in Brazil, said: “The excellent safety of the Chinese Kosing vaccine makes it more acceptable to the population than other vaccines being developed. “